Logo

Autobahn Initiates the P-I Trial of ABX-002 for the Treatment of Major Depressive Disorder

Share this

Autobahn Initiates the P-I Trial of ABX-002 for the Treatment of Major Depressive Disorder

Shots:

  • The P-I single/multiple-ascending dose clinical trial evaluates the safety, tolerability, PK & PD of ABX-002 in healthy volunteers. Following multiple-ascending study completion, Autobahn plans to initiate a P-Ib patient cohort to evaluate the safety & potential effects of ABX-002 in patients with MDD
  • Previously, the pre-clinical data evaluating ABX-002 had depicted a target engagement of ABX-002 in brain regions linked with depression along with a reduction in peripheral liabilities vs synthetic thyroid hormone (T3)
  • ABX-002 is a potent & selective, brain-boosting TRβ agonist that is being evaluated by Autobahn as a potential adjunctive treatment

Ref: Businesswire Image: Autobahn

Click here to­ read the full press release 

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions